My account
Injectables Orals Peptides Human Growth Hormone SARMs
Sign in
A
Anastrozole
B
Bacteriostatic water Boldenone undecylenate
C
Clenbuterol Clomiphene citrate Cabergoline
D
Drostanolone enanthate Drostanolone propionate Dehydroepiandrosterone (DHEA)
E
Erythropoietin Exemestane
F
Fluoxymesterone
H
Human chorionic gonadotropin Human growth hormone
L
Liothyronine sodium
M
Mecasermin Meldonium Mesterolone Methandienone Methenolone acetate Methenolone enanthate Melanotan-2
N
Nandrolone decanoate Nandrolone phenylpropionate
O
Oxandrolone Oxymetholone
S
Sildenafil citrate Stanozolol
T
Trenbolone enanthate Trestolone acetate Trenbolone acetate Testosterone undecanoate Testosterone propionate Testosterone base and suspension Tadalafil citrate Testosterone cypionate Testosterone enanthate Tamoxifen citrate Turinabol
Y
Yohimbine
Show 164 results
Manufacturers
Categories
Substances
Disagree
Home Substances
Triptorelin

Triptorelin

A-Z
Search for:
Ultima-Triptorelin 2
Ultima Pharmaceuticals
Triptorelin 2
Beligas Pharmaceuticals
Substance Overview and History

Triptorelin, a gonadotropin-releasing hormone (GnRH) agonist, effectively manages endometriosis by suppressing estradiol (E2) levels, reducing lesion growth, and alleviating symptoms like pelvic pain and dysmenorrhea. This hormone therapy works by downregulating GnRH receptors to lower luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels, achieving temporary chemical castration. The triptorelin acetate prolonged-release (PR) 1-month formulation has been a standard treatment, but the newer triptorelin pamoate PR 3-month option offers equivalent efficacy with fewer injections, reducing patient burden and improving compliance.

References:

Li, X., Li, H., Shi, H., Li, X., Zhou, R., Lu, D., Cai, Y., Zhou, Y., Cabri, P., Shi, X., Pedret-Dunn, A., and Leng, J., 2022. Assessment of two formulations of triptorelin in Chinese patients with endometriosis: A phase 3, randomized controlled trial. Advances in Therapy.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For more details consult with your doctor or healthcare professional.

FAQ
What is triptorelin?
Triptorelin is a gonadotropin-releasing hormone (GnRH) agonist used to manage hormone-dependent conditions like endometriosis and prostate cancer.
References:

Li, X., Li, H., Shi, H., Li, X., Zhou, R., Lu, D., Cai, Y., Zhou, Y., Cabri, P., Shi, X., Pedret-Dunn, A., and Leng, J., 2022. Assessment of two formulations of triptorelin in Chinese patients with endometriosis: A phase 3, randomized controlled trial. Advances in Therapy.

How does triptorelin work in treating endometriosis?
Triptorelin suppresses estradiol (E2) production by downregulating GnRH receptors, leading to reduced luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels and temporary chemical castration.
References:

Li, X., Li, H., Shi, H., Li, X., Zhou, R., Lu, D., Cai, Y., Zhou, Y., Cabri, P., Shi, X., Pedret-Dunn, A., and Leng, J., 2022. Assessment of two formulations of triptorelin in Chinese patients with endometriosis: A phase 3, randomized controlled trial. Advances in Therapy.

What are the benefits of triptorelin for endometriosis patients?
Triptorelin reduces endometriotic lesion growth, alleviates symptoms like pelvic pain and dysmenorrhea, and improves quality of life for patients.
References:

Li, X., Li, H., Shi, H., Li, X., Zhou, R., Lu, D., Cai, Y., Zhou, Y., Cabri, P., Shi, X., Pedret-Dunn, A., and Leng, J., 2022. Assessment of two formulations of triptorelin in Chinese patients with endometriosis: A phase 3, randomized controlled trial. Advances in Therapy.